Cerenome completes enrollment in glioblastoma drug trial
Cerenome Inc. (CNSY) completed enrollment in its Phase 2 ReSPECT-GBM trial for REYOBIQ, a radiotherapeutic for recurrent glioblastoma, with 32 patients. The company expects topline data in mid-2027 and plans an FDA meeting. Interim data showed median overall survival of 13 months, compared to 8 months historically. REYOBIQ is not yet approved by the FDA.
How this was made
The 30-second read
Why it matters
The enrollment completion removes a key operational hurdle and moves the program toward data readout, which could be a catalyst for the stock.
Market read
The news is a primary trial update that may modestly affect CNSY's price ahead of mid‑2027 data release.
What to watch
Potential competition from other glioblastoma therapies and the need for FDA approval.
Background
Cerenome is a small‑cap biotech developing a convection‑enhanced delivery radiotherapeutic for recurrent glioblastoma.
Ticker impact
Cerenome announced it has completed enrollment in its Phase 2 ReSPECT-GBM trial for REYOBIQ.
potential upside as investors price in upcoming Phase 2 data
The news is a primary disclosure of trial progress; no immediate catalyst but it reduces risk and may attract speculative buying ahead of data.
Market effects
Adds a positive data point for the neuro‑oncology biotech segment.
Limited to U.S. biotech investors.
Minimal global impact beyond niche biotech community.
Counterpoint
If Phase 2 data later disappoint, the enrollment news may have already priced in optimism.
Key entities
- companyCerenome Inc.
Developer of REYOBIQ, a radiotherapeutic for glioblastoma.
- government_agencyNational Cancer Institute
Provides award supporting the trial.
